Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: An open-label, randomised controlled trial

The Lancet

Volumn 385, Issue 9983, 2015, Pages 2173-2182

  Mfinanga, Sayoki ^a   Chanda, Duncan ^b   Kivuyo, Sokoine L ^a   Guinness, Lorna ^c   Bottomley, Christian ^c   Simms, Victoria ^c   Chijoka, Carol ^b   Masasi, Ayubu ^a   Kimaro, Godfather ^a   Ngowi, Bernard ^a   Kahwa, Amos ^a   Mwaba, Peter ^b   Harrison, Thomas S ^d   Egwaga, Saidi ^e   Jaffar, Shabbar ^c  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^b UNIVERSITY TEACHING HOSPITAL   (Zambia)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e MINISTRY OF HEALTH AND SOCIAL WELFARE   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPHOTERICIN B; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE; FLUCONAZOLE; FUNGUS ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ANTIFUNGAL AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COMMUNITY CARE; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORTALITY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; POINT OF CARE TESTING; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; RANDOMIZED CONTROLLED TRIAL; SCREENING; SENSITIVITY ANALYSIS; SOCIAL SUPPORT; SUPPORT GROUP; TANZANIA; TREATMENT DURATION; TUBERCULOSIS; VOLUNTARY WORKER; ZAMBIA; CLINICAL TRIAL; EPIDEMIOLOGY; HIV INFECTIONS; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; COMMUNITY HEALTH SERVICES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; PATIENT COMPLIANCE; TANZANIA; TREATMENT OUTCOME; ZAMBIA;

EID: 84930087694     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60164-7     Document Type: Article

References (33)

1. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries Lancet 367 2006 817 824
2. A Gupta, G Nadkarni, WT Yang et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis PloS One 6 2011 e28691
3. SD Lawn, AD Harries, X Anglaret, L Myer, R Wood Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa AIDS 22 2008 1897 1908
4. S Rosen, MP Fox Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review PLoS Med 8 2011 e1001056
5. IeDEA and ART Cohort Collaborations D Avila, KN Althoff et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries J Acquir Immune Defic Syndr 65 2014 e8 16
6. M Lahuerta, Y Wu, S Hoffman for the Identifying Optimal Models of HIV Care in sub-Saharan Africa Collaboration Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: findings from four sub-saharan African countries Clin Infect Dis 58 2014 432 441
7. CB Holmes, E Losina, RP Walensky, Y Yazdanpanah, KA Freedberg Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa Clin Infect Dis 36 2003 652 662
8. SD Lawn, AD Harries, G Meintjes, H Getahun, DV Havlir, R Wood Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa AIDS 26 2012 2121 2133
9. BJ Park, KA Wannemuehler, BJ Marston, N Govender, PG Pappas, TM Chiller Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS AIDS 23 2009 525 530
10. DG Storla, S Yimer, GA Bjune A systematic review of delay in the diagnosis and treatment of tuberculosis BMC Public Health 8 2008 15
11. NA Martinson, CJ Hoffmann, RE Chaisson Epidemiology of tuberculosis and HIV: recent advances in understanding and responses Proc Am Thorac Soc 8 2011 288 293
12. M Bates, V Mudenda, P Mwaba, A Zumla Deaths due to respiratory tract infections in Africa: a review of autopsy studies Curr Opin Pulm Med 19 2013 229 237
13. DJ Sloan, V Parris Cryptococcal meningitis: epidemiology and therapeutic options Clin Epidemiol 6 2014 169 182
14. JN Jarvis, T Bicanic, A Loyse et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes Clin Infect Dis 58 2014 736 745
15. JN Jarvis, A Boulle, A Loyse et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out AIDS 23 2009 1182 1183
16. A Kambugu, DB Meya, J Rhein et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy Clin Infect Dis 46 2008 1694 1701
17. J Campbell, G Dussault, J Buchan et al. A universal truth: no health without a workforce. Forum report - third global forum on human resources for health, Recife, Brazil 2013 Global Health Workforce Alliance and World Health Organisation Geneva
18. S Jaffar, B Amuron, S Foster for the Jinja trial team Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial Lancet 374 2009 2080 2089
19. V Simms, S Matiku, B Ngowi et al. Integrating public health research trials into health systems in Africa: individual or cluster randomisation? Trop Med Int Health 19 2014 123 127
20. E Marseille, MJ Giganti, A Mwango et al. Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia PloS One 7 2012 e51993
21. CA Scott, H Iyer, DL Bwalya et al. Retention in care and outpatient costs for children receiving antiretroviral therapy in Zambia: a retrospective cohort analysis PloS One 8 2013 e67910
22. JN Jarvis, SD Lawn, M Vogt, N Bangani, R Wood, TS Harrison Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa Clin Infect Dis 48 2009 856 862
23. N French, K Gray, C Watera et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults AIDS 16 2002 1031 1038
24. CA Liechty, P Solberg, W Were et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda Trop Med Int Health 12 2007 929 935
25. DB Meya, YC Manabe, B Castelnuovo et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings Clin Infect Dis 51 2010 448 455
26. JN Jarvis, TS Harrison, SD Lawn, G Meintjes, R Wood, S Cleary Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa PloS One 8 2013 e69288
27. R Rajasingham, DB Meya, DR Boulware Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care J Acquir Immune Defic Syndr 59 2012 e85 e91
28. A Loyse, H Thangaraj, NP Govender, T Harrison, T Bicanic on behalf of all authors Access to antifungal medicines in resource-poor countries - authors' reply Lancet Infect Dis 14 2014 371
29. LW Chang, J Kagaayi, G Nakigozi et al. Effect of peer health workers on AIDS care in Rakai, Uganda: a cluster-randomized trial PloS One 5 2010 e10923
30. MH Chung, BA Richardson, K Tapia et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes PLoS Med 8 2011 e1000422
31. A Boulle, M Schomaker, MT May et al. Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies PLoS Med 11 2014 e1001718
32. MC Marazzi, G Liotta, P Germano et al. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings AIDS Res Hum Retroviruses 24 2008 555 560
33. NA Menzies, AA Berruti, JM Blandford The determinants of HIV treatment costs in resource limited settings PloS One 7 2012 e48726